

Pretreatment Evaluation Before HCV Therapy

The following provides an overview of information needed to make choices regarding HCV therapy and to provide to most insurances when seeking prior authorization. Always consult individual company requirements before submitting applications for prior authorization.

Patient Identifier _____

Required Information	Results and Comments
HCV genotype and subtype	
Recent HCV RNA quantitative	
HCV treatment history: naive or experienced	
<ul style="list-style-type: none">If experienced, what was the regimen(s) and the outcome(s)?	
Liver staging: biopsy, <i>FibroSure</i> , or <i>FibroScan</i>	
<ul style="list-style-type: none">Note: some plans may not accept FIB-4 or APRI scores	
Liver transplant status	
For women of childbearing age receiving ribavirin:	
<ul style="list-style-type: none">Pregnancy test results	
<ul style="list-style-type: none">Current form of contraception	
HIV infection status	
<ul style="list-style-type: none">If positive, HIV-1 RNA level	
Serology: hepatitis A immunization	
Serology: hepatitis B immunization	
Complete blood count (CBC)	
Comprehensive metabolic panel (CMP)	
Urine toxicology	
Mental health notes/scores	

To discuss with patients regarding insurance prior authorizations:

- Prior authorization decisions may take several weeks.
- Some plans have preferred medications to treat HCV; it may be necessary to change regimens to another highly effective regimen based on insurance preference.
- Most plans have the option to appeal at least once if the decision comes back unfavorable.